The mechanism of action of the antiangiogenic drug bevacizumab seems less likely to directly impact the immune system by ADCC; however, an indirect effect on tumor vasculatures due to the STING/cGAS pathway could interfere with the bevacizumab antitumor activity. The gene discussed is CGAS; the disease is neoplasm.